| Previous Close | 81.08 |
| Open | 80.91 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 80.85 - 81.11 |
| 52 Week Range | 65.96 - 81.21 |
| Volume | 4,018,457 |
| Avg. Volume | 6,906,947 |
| Net Assets | 17.57B |
| NAV | 79.27 |
| PE Ratio (TTM) | N/A |
| Yield | 1.47% |
| YTD Return | 15.82% |
| Beta (3y) | 0.86 |
| Expense Ratio (net) | 0.14% |
| Inception Date | 1998-12-16 |
- Market Realist•2 days ago
How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017
In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.
- MarketWatch•2 days ago
Avoid health-care stocks as D.C. spins its wheels? No, here’s a case for buying them
The S&P is staying on track for its third up week in a row, largely shrugging off Russia-related shuffles in Washington and the big strikeout on health care. Today’s call says buy health-care stocks despite ...
- Market Realist•2 days ago
Johnson & Johnson Reports Growth in 2Q17
Headquartered in New Brunswick, New Jersey, Johnson & Johnson (JNJ) is one of the world's largest pharmaceutical and healthcare companies. It released its 2Q17 earnings on July 18, 2017.
